RYTM Rhythm Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RYTM

Price (delayed)

$98.24

Market cap

$6.76B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.11

Enterprise value

$6.7B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 25
Highlights
RYTM's revenue has soared by 54% YoY and by 10% QoQ
The gross profit has soared by 53% YoY and by 10% from the previous quarter
The quick ratio has increased by 23% year-on-year but it has declined by 17% since the previous quarter
Rhythm Pharmaceuticals's equity has decreased by 16% from the previous quarter
RYTM's net income is down by 12% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.rhythmtx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of RYTM

RYTM stock price

How has the Rhythm Pharmaceuticals stock price performed over time
Intraday
-1.04%
1 week
0.23%
1 month
-10.69%
1 year
-0.47%
YTD
-8.22%
QTD
-11.52%

Financial performance

How have Rhythm Pharmaceuticals's revenue and profit performed over time
Revenue
$239.92M
Gross profit
$213.53M
Operating income
-$200.63M
Net income
-$205.35M
Gross margin
89%
Net margin
-85.6%
RYTM's revenue has soared by 54% YoY and by 10% QoQ
The gross profit has soared by 53% YoY and by 10% from the previous quarter
The net margin has grown by 27% year-on-year and by 8% since the previous quarter
The operating margin has grown by 26% YoY and by 8% from the previous quarter

Price vs fundamentals

How does RYTM's price correlate with its fundamentals

Growth

What is Rhythm Pharmaceuticals's growth rate over time

Valuation

What is Rhythm Pharmaceuticals stock price valuation
P/E
N/A
P/B
65.38
P/S
28.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
27.93
The EPS has contracted by 3.3% YoY
RYTM's P/B is 26% above its 5-year quarterly average of 52.4 and 21% above its last 4 quarters average of 54.7
Rhythm Pharmaceuticals's equity has decreased by 16% from the previous quarter
RYTM's price to sales (P/S) is 57% lower than its 5-year quarterly average of 66.4 and 15% lower than its last 4 quarters average of 33.5
RYTM's revenue has soared by 54% YoY and by 10% QoQ

Efficiency

How efficient is Rhythm Pharmaceuticals business performance
The ROE has soared by 91% YoY and by 21% from the previous quarter
Rhythm Pharmaceuticals's return on invested capital has increased by 35% YoY and by 10% QoQ
The ROS has grown by 25% YoY and by 8% from the previous quarter
The ROA has grown by 9% YoY and by 2.4% from the previous quarter

Dividends

What is RYTM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RYTM.

Financial health

How did Rhythm Pharmaceuticals financials performed over time
The total assets is 99% more than the total liabilities
Rhythm Pharmaceuticals's current ratio has increased by 24% YoY but it has decreased by 17% from the previous quarter
The quick ratio has increased by 23% year-on-year but it has declined by 17% since the previous quarter
The debt is 96% smaller than the equity
The debt to equity has soared by 111% year-on-year and by 33% since the previous quarter
Rhythm Pharmaceuticals's equity has decreased by 16% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.